Subscribe

Xspray Pharma AB (publ) (XSPRAY.ST)

SEK14.90 -0.30 (-1.97%)
SE STO Healthcare Biotechnology
Address Råsundavägen 12 169 67
Solna, SE
CEO Per Andersson
Website xspraypharma.com
IPO 2017-09-28
ISIN SE0009973563

Explore sections of this company profile

Description

Xspray Pharma AB (publ), a pharmaceutical firm based in Solna, Sweden, specializes in developing protein kinase inhibitors for precise cancer treatments. Their current drug pipeline includes HyNap-Nilo, aimed at chronic myeloid leukemia; HyNap-Sora, which targets renal, liver, and several types of thyroid cancer; and HyNap-Dasa, intended for both chronic myeloid leukemia and acute lymphoblastic leukemia. Established in 2003, the company was formerly known as Xspray Microparticles AB until its name change to Xspray Pharma AB (publ) in 2017.

Market Cap & Enterprise Value
Merger & Acquisition History

No mergers or acquisitions recorded for this company.

Technical Outlook
Loading outlook…
Loading forecast...
Signal Summary Loading…
Indicator 1D1W2W3W1M
Each column is computed on that timeframe's candles (1D = daily, 1W ≈ weekly, 1M ≈ monthly), not on the same last day. ▲ bullish · ▼ bearish · — neutral. The Net row counts signals per column; hover any cell (or the indicator name) to see the exact rule behind it.
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
Indicative levels generated algorithmically. Not financial advice.
Risk Profile
Loading risk profile…
Price Chart
Averages
Trend
Price
Levels
Draw
SEK14.90 -0.30 (-1.97%)
Loading historical data…
Volume Profile
Loading…
Liquidity & share structure
Average Volume
167.7K
Beta
-0.03
Float Shares
19.48M
Free Float %
45.4%
Price Performance
1D5D1M3M6M YTD1Y3Y5Y10YMax
+0.82% +4.26% -10.42% -12.19% -6.31% -19.28% -24.85% -47.65% -72.46% -21.97% -21.97%
Rolling Volatility
Loading…
Drawdown
Loading…
Relative Strength
Loading…
Monthly Returns Heatmap
From To
Loading…
Annual Monthly Returns
Loading…
Daily Returns Distribution
vs.
Loading histogram data…

Revenue flow

Revenue by geography

Revenue by segment

From To

Revenue composition

From To

By product

By geography

Financial Statements

Income Statement

Balance Sheet

Cash Flow Statement

Key Metrics

Financial Ratios

Employees

Financial Growth (CAGR)

Market Data

Price Targets & DCF
Current price
14.90
DCF (Unlevered) 0.14 -99.1%

DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.

Ratings Trend (MoM)
Rating 2026-05 Change
Strong Buy 0 0
Buy 0 0
Hold 0 0
Sell 0 0
Strong Sell 0 0
Quality scores
Altman Z-Score
1.36
Distress
Piotroski F-Score
1 / 9
Weak
MOAT Score
0 / 10
No MOAT
Composite Rating
C-
Overall Score
1 / 5
Low
DCF Score
1 / 5
Low
ROE Score
1 / 5
Low
ROA Score
1 / 5
Low
D/E Score
2 / 5
Medium
P/E Score
1 / 5
Low
P/Book Score
3 / 5
Medium
Operational MOAT
✗ Below peers
  • ✓
    Revenue growth Biotechnology: +1.6%
    —
  • ✗
    EPS growth Biotechnology: +29.7%
    +48.3% ★ Q1'26: +25.4% (vs Q1'25)
  • ✗
    FCF margin FCF growth · Biotechnology: +16.2%
    —
  • ✗
    EBIT margin Biotechnology: +0.0%
    —
  • ✗
    ROIC Biotechnology: -16.1%
    -26.1% Q1'26: -20.9% (vs Q1'25)
  • ✗
    Share dilution Biotechnology: -3.4%
    +16.0% Q1'26: +12.4% (vs Q1'25)
  • ✗
    Debt / EBITDA Net debt/EBITDA · Biotechnology: 0.16×
    -1.09× Q1'26: -1.24× (vs Q1'25)
Valuation Multiples From To
DCF Interactive Model (UFCF)
Projection years:
Market assumptions
▶ WACC components (optional)
Ke (Cost of Equity) = Rf + β (-0.06) × ERP
WACC = 85% × Ke + 15% × Kd (9.9%) × (1−t)

Modifying these values recalculates WACC automatically.

Business assumptions
—
Intrinsic value (base): 0.14 Current price: 14.90
Enterprise Value: — Equity Value: — Terminal Value: — TV as % of EV: —

Base values reflect the latest available data for this company and market conditions.

Consensus Estimates
Metric Dec 2020
actual 		Dec 2021
actual 		Dec 2022
actual 		Dec 2023
actual 		Dec 2024
actual 		Dec 2025
actual 		Dec 2026
1 Rev. Ana.
1 EPS Ana. 		Dec 2027
1 Rev. Ana.
1 EPS Ana. 		Dec 2028
1 Rev. Ana.
1 EPS Ana.
Revenue
—
est: 200.00M (-100.0%)
—
est: 437.3K (-100.0%)
—
est: 424.4K (-100.0%)
—
est: -196.0K (+100.0%)
—
est: 4.80M (-100.0%)
—
est: 24.30M (-100.0%)
95.00M
95.00M – 95.00M
+290.9% YoY
727.00M
727.00M – 727.00M
+665.3% YoY
1.30B
1.30B – 1.30B
+78.7% YoY
EBITDA
-50.99M
-87.82M
-122.13M
-169.82M
-277.76M
-156.27M
—
— – —
—
— – —
—
— – —
EBIT
-52.40M
-96.69M
-131.66M
-179.01M
-283.24M
-161.85M
—
— – —
—
— – —
—
— – —
Net Income
-52.30M
est: 205.26M (-125.5%)
-96.70M
est: -126.18M (+23.4%)
-130.27M
est: -272.44M (+52.2%)
-179.67M
est: -264.23M (+32.0%)
-285.52M
est: -277.38M (-2.9%)
-171.44M
est: -97.50M (-75.8%)
-238.41M
-238.41M – -238.41M
-144.5% YoY
126.90M
126.90M – 126.90M
+153.2% YoY
572.96M
572.96M – 572.96M
+351.5% YoY
SGA
47.10M
58.38M
109.60M
169.57M
203.88M
145.52M
—
— – —
—
— – —
—
— – —
EPS
-3.01
est: 6.19 (-148.6%)
-4.98
est: -3.81 (-30.8%)
-6.13
est: -8.22 (+25.4%)
-6.76
est: -6.87 (+1.6%)
-8.62
est: -7.21 (-19.5%)
-4.46
est: -2.54 (-75.9%)
-6.20
-6.20 – -6.20
-144.5% YoY
3.30
3.30 – 3.30
+153.2% YoY
14.90
14.90 – 14.90
+351.5% YoY
Historical Ratings (3M)
Date Rating Overall DCF ROE ROA D/E P/E P/B
2026-05-11 C- 1/5 1/5 1/5 1/5 2/5 1/5 3/5
2026-05-08 C- 1/5 1/5 1/5 1/5 2/5 1/5 3/5
2026-05-07 C- 1/5 1/5 1/5 1/5 2/5 1/5 3/5
2026-05-06 C- 1/5 1/5 1/5 1/5 2/5 1/5 3/5
2026-05-05 C- 1/5 1/5 1/5 1/5 2/5 1/5 3/5
2026-05-04 C- 1/5 1/5 1/5 1/5 2/5 1/5 3/5
2026-04-30 C- 1/5 1/5 1/5 1/5 2/5 1/5 3/5
2026-04-29 C- 1/5 1/5 1/5 1/5 2/5 1/5 3/5
2026-04-28 C- 1/5 1/5 1/5 1/5 2/5 1/5 3/5
2026-04-27 C- 1/5 1/5 1/5 1/5 2/5 1/5 3/5
2026-04-24 C- 1/5 1/5 1/5 1/5 1/5 1/5 3/5
2026-04-23 C- 1/5 1/5 1/5 1/5 1/5 1/5 3/5
2026-04-22 C- 1/5 1/5 1/5 1/5 1/5 1/5 3/5
2026-04-21 C- 1/5 1/5 1/5 1/5 1/5 1/5 3/5
2026-04-20 C- 1/5 1/5 1/5 1/5 1/5 1/5 3/5
2026-04-17 C- 1/5 1/5 1/5 1/5 1/5 1/5 3/5
2026-04-16 C- 1/5 1/5 1/5 1/5 1/5 1/5 3/5

Owner Earnings

Owner's Earnings (history) From To
Owner alignment
Owner's Earnings TTM
-124.01B
OE per share TTM
-3,809.06
Owner's Yield
-12,226.13%
Maintenance CapEx ratio
—
Maint CapEx / Avg PPE
142,768.0%

Ownership Overview

Ownership breakdown

Ownership breakdown not available.

At a glance
Institutional holders
—
Total invested
—
Insider transactions (90d)
0
Beneficial owners (>5%)
0
Beneficial owners (>5%)

No beneficial ownership filings recorded.

Institutional Activity (13F)

Institutional ownership trend

Institutional history not available.

Top institutional holders

Top holders not available.

ETF Ownership

Top ETFs holding this stock

This company is not held by any ETF in our universe.

Insider Activity

Insider Activity — Latest Quarter

No insider activity available.

Insider buys vs sells (history)

Insider history not available.

Recent insider transactions

No recent insider transactions.

Executive team

Top executives
Shares Outstanding
42.93M

Executive compensation

Executive compensation (annual)

Executive compensation not available.

CEO compensation breakdown

No CEO compensation history available.

Proxy statements

Proxy statements (DEF 14A)

No proxy statements available for this company yet.

Recent SEC filings

Recent SEC filings

No SEC filings available for this company yet.

Executive team

NameTitleCompensationGender
Per Andersson Chief Executive Officer & Chief Scientific Officer 5M —
Linda Glimberg Chief Operating Officer — female
Mikael Von Euler-Chelpin Chief Medical Officer — —
Mustafa Demirbüker Co-Founder and Science Director — —
Niklas Adenborg Chief Financial Officer — male
ESG Score History

No data available for this company.

Senate Trading Activity

No Senate trading activity found for this company.

House Trading Activity

No House trading activity found for this company.

Market share among peers
Peer comparison — filtered group (TTM)
Your opinion

Share your view on this stock and instantly see how the community has voted over the last 6 months.

These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.

Dividend history

Earnings history

Earnings reports

Stock splits

Related companies

Largest companies in Biotechnology